Vaccines against viral pathogens
The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli , CHO cells, yeast cells) that would require subsequent endotoxin assays/removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.
1 . A viral peptide (VP) conjugate (VP-hC) or a VP oligomer (VPhC) comprising one or more viral peptides (VPs) covalently attached to a hapten carrier (hC), the hC comprising a monomeric peptide comprising SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31.
2 . The VP conjugate or VP oligomer of claim 1 , wherein the monomeric peptide forms a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nanomer, or decamer.
3 . The VP conjugate or VP oligomer of claim 1 , wherein the one or more VPs are obtained from a Coronavirus, an Influenza virus, a Respiratory Syncytial virus (RSV), Human Papillomavirus (HPV), Dengue virus, Yellow Fever virus (YFV), or West Nile virus (WNV) and optionally, wherein the one or more VPs are obtained from a SARS-COV-2 virus.
4 . The VP conjugate or VP oligomer of claim 3 , wherein the one or more VPs comprise one or more S peptides of the spike glycoprotein or the membrane protein (M) of a SARS-COV-2 virus, and optionally, wherein the one or more S peptides comprise S1, S2, S3, S4, S5, and/or S6, and the membrane peptide comprises M1.
5 . The VP conjugate or VP oligomer of claim 4 , wherein the one or more VPs comprise amino acid sequence SEQ ID NO: 136, 120, 132, 119, 118, 117, and/or 130.
6 . The VP conjugate or VP oligomer of claim 1 , wherein the one or more VPs comprise a modified VP, the modified VP comprising a modified amino acid sequence, and optionally, wherein one or more cysteines (C) are substituted with serine(S), or wherein the modified VP comprises amino acid sequence SEQ ID NO: 139 or 140.
7 . The VP conjugate or VP oligomer of claim 5 , wherein the one or more VPs comprise additional amino acids at its N- and/or C-terminus, the additional amino acids being V (valine) and/or DDEDC (SEQ ID NO: 116), and optionally, wherein the one or more VPs comprise amino acid sequence SEQ ID NO: 73, 57, 69, 115, 55, 54, and/or 67.
8 . The VP conjugate or VP oligomer of claim 7 , wherein the one or more VPs further comprise a protecting group at its N- and/or C-terminus, and optionally, wherein the protecting group comprises an acetyl group and/or an amide group.
9 . The VP conjugate or VP oligomer of claim 1 , wherein the VP conjugate or VP oligomer comprises two or more VPs from different sources or strains of SARS-COV-2.
10 . The VP conjugate or VP oligomer of claim 1 , wherein the one or more VPs are conjugated to the hC through lysine (K) on the monomeric peptide.
11 . The VP conjugate or VP oligomer of claim 1 , wherein the one or more VPs or the monomeric peptide further comprises one or more immunomodulators or additional haptens, one or more spacers or linkers between the hapten or immunomodulator and the monomeric peptide, and/or one or more residues for correct processing of the one or more T-cell epitopes.
12 . The VP conjugate or VP oligomer of claim 11 , wherein the one or more haptens or immunomodulators comprise one or more additional VPs, one or more T-cell epitopes, and/or one or more B-cell epitopes.
13 . The VP conjugate or VP oligomer of claim 1 , wherein the VP conjugate or VP oligomer comprises a hC comprising amino acid sequence SEQ ID NO: 112 or 113.
14 . A pharmaceutical composition comprising the VP conjugate or VP oligomer of claim 1 and a pharmaceutically acceptable excipient, and optionally, wherein the excipient comprises MPL A.
15 . A method of treating a subject having a viral disease or infection and/or preventing a subject from developing a viral disease or infection, wherein the method comprises administering to the subject, an effective amount of the composition of claim 14 , wherein the VP induces an immune response in the subject, thereby treating the subject having the viral disease or infection or preventing the subject from developing the viral disease or infection, and optionally the viral disease or infection is caused by SARS-COV-2.
16 . The method of claim 15 , wherein the subject is a mammal, and optionally the mammal is a human.
17 . A method of enhancing immunogenicity of a VP, wherein the method comprises:
(a) obtaining a monomeric peptide of the VP conjugate of claim 1 , allowing the monomeric peptide to self-assemble into a hC, and conjugating a VP to the hC to obtain a VP-hC conjugate;
or
(b) synthesizing a VP monomeric peptide (VPMP), wherein the VPMP comprises a monomeric peptide (MP) of the VP oligomer of claim 1 and a VP, and allowing the VPMP to self-assemble into a VPhC oligomer.
18 . A method of preparing a VP therapeutic or vaccine, wherein the method comprises:
(a) obtaining a monomeric peptide of the VP conjugate or VP oligomer of claim 1 ,
allowing the monomeric peptide to self-assemble into a hC, and
conjugating a VP to the hC to obtain a VP-hC conjugate, thereby obtaining a VP therapeutic or vaccine;
or
(b) synthesizing a VP monomeric peptide (VPMP), wherein the VPMP comprises a monomeric peptide of claim 1 and a VP of claim 1 , and allowing the VPMP to self-assemble into a VPhC oligomer, thereby obtaining a VP therapeutic or vaccine.
19 . The method of claim 17 , wherein the method further comprises the monomeric peptide self-assembling into a hexameric hC.
20 . A peptide immunogen comprising amino acid SEQ ID NO: 73, 57, 69, 115, 55, 54, or 67.
21 . The peptide immunogen of claim 20 , wherein the N-terminus and/or the C-terminus of the peptide immunogen comprise or comprises a protecting group, and optionally, wherein the protecting group of the N-terminus comprises an acetyl group and the protecting group of the C-terminus comprises an amide group.
22 . A peptide scaffold comprising amino acid SEQ ID NO: 112 or 113.
23 . The peptide scaffold of claim 22 , wherein the N-terminus and/or the C-terminus of the peptide scaffold comprise or comprises a protecting group, and optionally, wherein the protecting group of the N-terminus comprises an acetyl group and the protecting group of the C-terminus comprises an amide group.
24 . A composition comprising one or more peptide immunogens of claim 20 and a peptide scaffold comprising amino acid SEQ ID NO: 112 or 113.
25 . The composition of claim 24 , wherein the one or more peptide immunogens are attached to the peptide scaffold.
26 . The composition of claim 24 , wherein the one or more peptide immunogens are not attached to the peptide scaffold.
27 . The method of claim 18 , wherein the method further comprises the monomeric peptide self-assembling into a hexameric hC.
28 . The peptide immunogen of claim 20 , wherein the peptide immunogen comprises amino acid SEQ ID NO: 73, 55, or 54.
29 . The VP-hC or a VPhC of claim 1 , wherein the VP conjugate comprises one or more VPs conjugated to the hC; and wherein the VP oligomer comprises one or more VPs incorporated into the hC.